Journal of Surgery Concepts & Practice >

2023 , Vol. 28 >Issue 06: 520 - 523

DOI: https://doi.org/10.16139/j.1007-9610.2023.06.06

Experts forum

Combination of targeted multikinase inhibitor and radioiodine: a new strategy of treatment for advanced differentiated thyroid carcinoma

Expand
  • Department of Nuclear Medicine, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Nanjing 210029, China

Received date: 2023-10-08

  Online published: 2024-03-04

Fold

Abstract

Advanced differentiated thyroid carcinoma (ADTC) lacks effective treatment options, and has a poor prognosis, which is an urgent clinical problem to be resolved. Targeted multikinase inhibitor(MKI) has been approved for the treatment of radioiodine refractory differentiated thyroid carcinoma, and have recently been recommended as a preoperative neoadjuvant therapy agents for locally ADTC. Although radioiodine therapy is the standard postoperative treatment for ADTC, it has certain limitations. MKI combined with radioiodine therapy is expected to become a new strategy of treatment for ADTC.

Key words： Advanced differentiated thyroid carcinoma; Multikinase inhibitor; Radioiodine; 131I

Cite this article

LIU Wei . Combination of targeted multikinase inhibitor and radioiodine: a new strategy of treatment for advanced differentiated thyroid carcinoma[J]. Journal of Surgery Concepts & Practice, 2023 , 28(06) : 520 -523 . DOI: 10.16139/j.1007-9610.2023.06.06

References

[1] PIZZATO M, LI M, VIGNAT J, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020[J]. Lancet Diabetes Endocrinol, 2022, 10(4):264-272.
[2] ZENG H, CHEN W, ZHENG R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5):e555-e567.
[3] COCA-PELAZ A, RODRIGO J P, SHAH J P, et al. Recurrent differentiated thyroid cancer: the current treatment options[J]. Cancers (Basel), 2023, 15(10):2692.
[4] HAUGEN B R, ALEXANDER E K, BIBLE K C, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1):1-133.
[5] DURANTE C, HADDY N, BAUDIN E, et al. Long-term outcome of 444 patients with distant metastases from papi-llary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy[J]. J Clin Endocrinol Metab, 2006, 91(8):2892-2899.
[6] RUEGEMER J J, HAY I D, BERGSTRALH E J, et al. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables[J]. J Clin Endocrinol Metab, 1988, 67(3):501-508.
[7] RATAJCZAK M, GAWE? D, GODLEWSKA M. Novel inhibitor-based therapies for thyroid cancer - an update[J]. Int J Mol Sci, 2021, 22(21):11829.
[8] 中国医师协会外科医师分会甲状腺外科医师委员会, 中国研究型医院学会甲状腺疾病专业委员会, 中国医疗保健国际交流促进会普通外科学分会, 等. 局部进展期甲状腺癌新辅助治疗中国专家共识(2023版)[J]. 中国实用外科杂志, 2023, 43(8):841-848.
  The Thyroid Surgeon Committee of the Surgical Branch of the Chinese Medical Association, The Thyroid Disease Professional Committee of the Chinese Research Hospital Association, The General Surgery Branch of the Chinese Healthcare International Exchange Promotion, et al. Association Chinese expert consensus on neoadjuvant therapy for locally advanced thyroid cancer (2023 version)[J]. Chin J Pract Surg, 2023, 43(8):841-848.
[9] HAUGEN B R, SHERMAN S I. Evolving approaches to patients with advanced differentiated thyroid cancer[J]. Endocr Rev, 2013, 34(3):439-455.
[10] RUSSELL M D, KAMANI D, RANDOLPH G W. Modern surgery for advanced thyroid cancer: a tailored approach[J]. Gland Surg, 2020, 9(Suppl 2):S105-S119.
[11] SHONKA D C Jr, HO A, CHINTAKUNTLAWAR A V, et al. American head and neck society endocrine surgery section and international thyroid oncology group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment[J]. Head Neck, 2022, 44(6):1277-1300.
[12] NIXON I J, SIMO R, NEWBOLD K, et al. Management of invasive differentiated thyroid cancer[J]. Thyroid, 2016, 26(9):1156-1166.
[13] FATOURECHI V, HAY I D, JAVEDAN H, et al. Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer[J]. J Clin Endocrinol Metab, 2002, 87(4):1521-1526.
[14] SABRA M M, GREWAL R K, TALA H, et al. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans[J]. Thyroid, 2012, 22(9):877-883.
[15] ILHAN H, MUSTAFA M, BARTENSTEIN P, et al. Rate of elimination of radioiodine-avid lymph node metastases of differentiated thyroid carcinoma by postsurgical radioiodine ablation. A bicentric study[J]. Nuklearmedizin, 2016, 55(6):221-227.
[16] RONGA G, FILESI M, MONTESANO T, et al. Lung metastases from differentiated thyroid carcinoma. A 40 years' experience[J]. Q J Nucl Med Mol Imaging, 2004, 48(1):12-19.
[17] BROSE M S, NUTTING C M, JARZAB B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet, 2014, 384(9940):319-328.
[18] SCHLUMBERGER M, TAHARA M, WIRTH L J, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med, 2015, 372(7):621-630.
[19] FALCHOOK G S, MILLWARD M, HONG D, et al. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer[J]. Thyroid, 2015, 25(1):71-77.
[20] Huang N S, Wei W J, Xiang J, et al. The efficacy and safety of anlotinib in neoadjuvant treatment of locally advanced thyroid cancer: a single-arm phase Ⅱ clinical trial[J]. Thyroid, 2021, 31(12):1808-1813.
[21] OH J M, KALIMUTHU S, GANGADARAN P, et al. Reverting iodine avidity of radioactive-iodine refractory thyroid cancer with a new tyrosine kinase inhibitor (K905-0266) excavated by high-throughput NIS (sodium iodide symporter) enhancer screening platform using dual reporter gene system[J]. Oncotarget, 2018, 9(6):7075-7087.
[22] SUZUKI K, IWAI H, UTSUNOMIYA K, et al. Efficacy of combination therapy with lenvatinib and radioactive iodine in thyroid cancer preclinical model[J]. Int J Mol Sci, 2022, 23(17):9872.
[23] SUZUKI K, IWAI H, UTSUNOMIYA K, et al. Combination therapy with lenvatinib and radiation significantly inhibits thyroid cancer growth by uptake of tyrosine kinase inhibitor[J]. Exp Cell Res, 2021, 398(1):112390.
[24] SHEU N W, JIANG H J, WU C W, et al. Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review[J]. World J Surg Oncol, 2019, 17(1):84.
[25] SHI L, YOU Q, WANG J, et al. Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC)[J]. Endocrine, 2022, 78(1):68-76.
[26] DOTINGA M, VRIENS D, VAN VELDEN F H P, et al. Reinducing radioiodine-sensitivity in radioiodine-refractory thyroid cancer using lenvatinib (RESET): study protocol for a single-center, open label phase Ⅱ trial[J]. Diagnostics (Basel), 2022, 12(12):3154.
[27] LIN Y S. The efficacy and safety of anlotinib hydrochloride or penpulimab in combination with RAI in patients with local advanced or metastatic differentiated thyroid cancer: a randomized, open-label, exploratory clinical trial[EB/OL]. [2023-10-08]. https://www.clinicaltrials.gov/study/NCT04952493 .
[28] SONG H J, QIU X, HE Z, et al. The efficacy and safety of sequential use of anlotinib and 131I for locally advanced or metastatic differentiated thyroid cancer: a single-arm phase Ⅱ clinical trial[J]. J Clin Oncol, 2023, 41(16 suppl):e18102-e18102.
Options
Outlines

/

〈 〉